“What [Gilead Sciences] has done with [the hepatitis C drug Sovaldi] will break the country. It will make pharmacy benefits no longer sustainable. Companies just aren’t going to be able to handle paying for this drug.”
— Steve Miller, chief medical officer for Express Scripts Holding Co., in an interview with Bloomberg.
No comments:
Post a Comment